| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
AZD-5672 targets CCR5, a chemokine receptor involved in inflammation and immune responses. It is a potent and selective CCR5 antagonist with an IC50 of 0.32 nM. By inhibiting CCR5, it modulates immune responses and has potential applications in inflammatory diseases such as rheumatoid arthritis. It also has moderate activity against the hERG ion channel and is a substrate for P-glycoprotein.
|
|---|---|
| ln Vitro |
The concentration-dependent inhibition of P-gp-mediated digoxin transport in Caco-2 cells by AZD-5672 (0, 0.1, 0.3, 1, 3, 10, 30 and 100 μM) had a mean apparent IC50 of 32 μM [2].
In vitro, AZD-5672 inhibits CCR5 with an IC50 of 0.32 nM. It shows moderate activity against the hERG ion channel with a binding IC50 of 7.3 μM. It is a substrate for human P-glycoprotein and inhibits P-gp-mediated digoxin transport with an IC50 of 32 μM. These properties are important for understanding its pharmacokinetic and safety profile. |
| ln Vivo |
In vivo pharmacokinetic data for AZD-5672 (Compound 1) [1]: Species CIa (mL/min/kg) Vssa (L/kg) t1/2a (h) Fb (%) Rat 28 5.3 2.6 38 Dog 18 5.7 3.9 86a AZD-5672 dosage 1-2 mg/kg IVb AZD-5672 dose 2-5 mg/kg oral
In vivo, AZD-5672 is an orally active CCR5 antagonist. It can be used in the research of rheumatoid arthritis. Its oral bioavailability and potent CCR5 antagonism make it a valuable tool for studying the role of CCR5 in inflammatory diseases. |
| Enzyme Assay |
The activity of AZD-5672 can be assessed using cell-based assays to measure its inhibition of CCR5-mediated signaling. Cells expressing CCR5 are treated with a CCR5 ligand (e.g., CCL5/RANTES) in the presence or absence of varying concentrations of AZD-5672. The inhibition of downstream signaling, such as calcium mobilization or chemotaxis, is measured. The IC50 for CCR5 antagonism is determined from dose-response curves. Its binding to hERG and P-gp can be assessed using specific assays.
|
| Cell Assay |
To evaluate the cellular effects of AZD-5672, immune cells such as T cells or monocytes are treated with the compound, and the inhibition of CCR5-mediated chemotaxis and signaling is assessed. The effects on immune function and inflammation are evaluated.
|
| Animal Protocol |
In vivo studies with AZD-5672 typically involve administration to animals via oral routes. In models of rheumatoid arthritis or other inflammatory diseases, the compound's effects on inflammation, immune cell infiltration, and disease progression are assessed.
|
| ADME/Pharmacokinetics |
AZD-5672 has a molecular formula of C25H28F3N5O3S and a molecular weight of 535.58. Its CAS number is 780750-65-4. The compound is an orally active, potent, and selective CCR5 antagonist. It is soluble in DMSO and other organic solvents. The purity is typically >98%.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for AZD-5672 are not detailed in the available literature. However, its moderate activity against the hERG ion channel suggests a potential for cardiac side effects at high concentrations. As with all research compounds, standard safety precautions should be taken during handling.
|
| References |
|
| Additional Infomation |
Azd5672 has been used in trials investigating pharmacokinetics, renal impairment, and basic science and treatment of rheumatoid arthritis.
AZD-5672 is an orally active, potent, and selective CCR5 antagonist used in research on inflammatory diseases. It has been investigated for the treatment of rheumatoid arthritis. It is a valuable tool for studying the role of CCR5 in inflammation and immune responses. It is not a clinically approved drug. |
| Molecular Formula |
C32H38F2N2O5S2
|
|---|---|
| Molecular Weight |
632.781333446503
|
| Exact Mass |
632.219
|
| CAS # |
780750-65-4
|
| Related CAS # |
527744-53-2 (HCl);780750-65-4;
|
| PubChem CID |
16007088
|
| Appearance |
White to light brown solid powder
|
| LogP |
6.948
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
43
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCN(C1CCN(CC1)CC[C@H](C2=CC=C(C=C2)S(=O)(=O)C)C3=CC(=CC(=C3)F)F)C(=O)CC4=CC=C(C=C4)S(=O)(=O)C
|
| InChi Key |
SCXSQUUTGCWHFU-WJOKGBTCSA-N
|
| InChi Code |
InChI=1S/C32H38F2N2O5S2/c1-4-36(32(37)19-23-5-9-29(10-6-23)42(2,38)39)28-13-16-35(17-14-28)18-15-31(25-20-26(33)22-27(34)21-25)24-7-11-30(12-8-24)43(3,40)41/h5-12,20-22,28,31H,4,13-19H2,1-3H3/t31-/m1/s1
|
| Chemical Name |
N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~52.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5803 mL | 7.9016 mL | 15.8033 mL | |
| 5 mM | 0.3161 mL | 1.5803 mL | 3.1607 mL | |
| 10 mM | 0.1580 mL | 0.7902 mL | 1.5803 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
